We extend our sincere appreciation for the support of our corporate sponsors. Their generosity provides vital funding needed to fulfill our mission to make a lasting and positive difference in the lives of people who have kidney disease.
THANK YOU TO OUR CORPORATE PARTNERS
DIAMOND
Fresenius Kidney Care, a division of Fresenius Medical Care North America (FMCNA), provides dialysis treatment and services to more than 190,000 people with kidney disease at more than 2,400 facilities nationwide. Fresenius Kidney Care supports people by helping to address both the physical and emotional aspects of kidney disease through personalized care, education and lifestyle support services so they can lead meaningful and fulfilling lives.
U.S. Renal Care serves more than 23,000 patients in 300 dialysis facilities in 31 states and the Territory of Guam with a unique business model, developing and operating dialysis centers in joint venture partnerships with leading local nephrologists.
PLATINUM
Akebia Therapeutics is a biopharmaceutical company with the purpose to better the life of each person impacted by kidney disease. We have both a commercially available product and a potential first-in-class product candidate for the treatment of anemia due to chronic kidney disease. We are located in the biotech hub of Cambridge, Massachusetts, where we are inspired by our peers and dedicated to working with our partners, patients, advocacy organizations and the broader kidney community.
GOLD
Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses.
At Ardelyx®, we are dedicated to improving the lives of patients by discovering, developing and commercializing first-in-class targeted therapies that advance patient care. Using our discovery model, Ardelyx scientists identified new biological mechanisms and pathways that enabled us to develop drug candidates designed to address significant unmet medical needs with the goal of improving outcomes for patients. Visit Ardelyx.com to learn more.
SILVER
Astrazenca is a global, science-led biopharmaceutical business whose innovative medicines are used by millions of patients worldwide.
Alexion The work we do is guided by people living with rare and devastating diseases. We are driven to continuously innovate and create meaningful value in all we do to help patients and families fully live their best lives.
DaVita is a leading provider of dialysis services to patients with chronic kidney failure and end stage renal disease.
BRONZE
Since our Founder and Board Chairman Dr. Keith Johnson opened the first clinic in 1971 to care for eight patients in Nashville, Tenn., Dialysis Clinic, Inc. (DCI) has grown to be the nation’s largest not-for-profit dialysis provider with more than 240 locations across 28 states, serving nearly 14,000 patients each day. DCI’s mission states, “The care of the patient is our reason for existence.” DCI prioritizes a holistic approach and offers hemodialysis, home hemodialysis and peritoneal dialysis treatment options. DCI empowers patients to live meaningful and productive lives while also delivering high quality kidney care, saving lives and reducing hospitalizations. DCI is committed to advancing care through research and education to improve the lives of patients along the continuum of kidney health.
ENGAGE
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases (including FSGS). In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.